Radiesse is a FDA-approved subdermal implant (injected below the surface of the skin) indicated for:

• the correction of moderate to severe facial wrinkles and folds (nasolabial folds)
• for restoration and/or correction of the signs of facial fat loss (lipoatrophy) in patients with HIV.

Radiesse is composed of synthetic calcium hydroxylapatite microspheres suspended in a water-based gel carrier. Radiesse is injected subdermally by a healthcare provider. The number of treatments needed are determined by a healthcare professional based upon the individual needs of the patient.

According to the manufacturer, Radiesse is an injectable filler that works by immediately restoring facial volume to smooth out the signs of aging. Once injected, it stimulates the production of natural collagen for results that may last a year or more. Visible results can be seen immediately.

Radiesse is available in a 1.5, 1.3, 0.8 and 0.3 cc syringe size. Radiesse is injected using a 25 to 27 gauge needle, and is FDA approved to mix with 2% lidocaine (an anesthetic) to control discomfort during injection for nasolabial folds, if needed. The safety and effectiveness of mixing 2% lidocaine and Radiesse injectable implant for use in patients with facial fat loss (lipoatrophy) in HIV has not been studied. Allergy or skin testing is not required prior to Radiesse treatment. For most patients, little to no recovery time is needed after Radiesse injections.